Etanercept is a fully-human soluble receptor Fc fusion protein. Thearticlesummarizes the results of clinical studies of etanercept and immunogenicity of TNF inhibitors. Formation of antidrug antibodies can modify their pharmacokinetics, efficacy and safety. Etanercept is less immunogenic compared with the other TNF inhibitors. Clinical studies showed that etanercept is effective as monotherapy and can be given alone to patients who are intolerant of metothrexate. Recent evidence suggest that the dose of etanercept can be reduced once a treatment target has been sustained.
Etanercept, immunogenicity, modification of treatment.